View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fi...

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-Financial Performance Report (fiscal year 2024). Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to the growing interest of institutional and individual shareholders,...

 PRESS RELEASE

GENFIT : Publication du rapport de performance extra-financière 2025 (...

GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024) Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui la publication de son rapport de performance extra-financière 2025 (exercice 2024).  Depuis 2022, GENFIT publie un rapport de performance extra-financière détaillé en réponse à l’intérêt croissant des actionnaires ins...

Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk
Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk
Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk
Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk
Emna Ben Bdira ... (+2)
  • Emna Ben Bdira
  • Maxime Kogge
Emna Ben Bdira ... (+2)
  • Emna Ben Bdira
  • Maxime Kogge
Oscar Rodriguez
  • Oscar Rodriguez

ACERINOX: 1Q’25 RESULTS (ANÁLISIS BANCO SABADELL)

1Q'25 vs. 1Q'24 Results Sales: € 1.5 Bn (+4.7% vs. +3.4% BS(e) and -0.3% consensus); EBITDA: € 102 M (-8.1% vs. -1.8% BS(e) and -1.8% consensus); EBIT: € 53 M (-25.4% vs. -4.2% BS(e) and -8.5% consensus); Net Profit: € 10 M (-81.1% vs. -28.3% BS(e) and -28.3% consensus).

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch